Traditional immunotherapy biomarkers such as PD-L1 expression, tumor mutational burden, or immune infiltration scores have proven inadequate to fully capture the complexity and dynamic interactions occurring within the tumor microenvironment (9). Here, CD274 is linked to neoplasm.